Patent Application
20230076683
The present disclosure relates to formulations for exposure to an intestine lumen environment and subsequent delivery of an active agent across or within a wall of the intestine.
Medical treatment often involves delivery of an active or therapeutic agent administered to patients using various means including transdermal, oral, or injectable delivery. Each method has associated advantages as well as disadvantages which must be overcome in order to deliver effective therapy. For example, injections allow direct systemic delivery without involving the gastrointestinal (GI) tract and first pass metabolism. However, injections often involve pain, risk of infection, inconvenient devices for administration, fluid form of drug with limited stability or transport and storage limitations, and which frequently affect patient compliance and quality of life. With conventional oral formulations, some active agents, including antibodies, proteins, and peptides, are not able to be delivered orally due to the sensitivity of the molecules to gastric pH, enzymatic degradation in the GI tract, presence of mucus, as well as the low permeation characteristics of the intestine wall for the size and polarity of this group of molecules. Thus, there is a need for new and improved methods and devices for oral delivery of proteins, antibodies, and peptides to a patient.
Orally administered, intestinal transmucosal drug delivery is an area of interest because of the potential of delivering systemically acting drugs with a high relative bioavailability due to increased blood flow, the potential of locally delivering therapeutic agents to a local site in the intestine, and the convenience of the oral application route for improved patient compliance. An orally administered transintestinal patch which does not involve pain, can deliver an active agent to the blood while also enabling smooth, consistent, and safe penetration of an active agent into the intestinal wall.
However, most of the gastrointestinal tract is covered with a defending layer of mucus which is a continuously renewed viscous fluid containing various categories of agents, such as antiseptic lysozymes, proteins, and glycoprotein mucins. The tightly lined epithelial cells with intercellular spaces sealed by tight junctions also form a barrier. These defending layers provide additional challenge to transmucosal drug delivery. First, the viscous liquid traps and slows down the intrusion of foreign matter, thus allowing time for enzymatic and other defense mechanisms to degrade and/or kill the foreign body. Secondly, the viscous liquid fluid continuously cleans and washes the surface of the mucosal tissue as it is expelled from the tissue. As such, a significant amount of drug may be wasted using conventional techniques.
Although intestinal transmucosal drug delivery has advanced over the years, there are numerous unique challenges associated with intestinal patch deployment and release of an active agent, especially macromolecules including biologics, in the intestinal wall for a period sufficient to allow for the transfer without early release of an active agent in the lumen of the intestine where it can be degraded. Attempts to provide oral delivery of biologics by incorporating protease inhibitors, mucoadhesive polymers, cross-linked enzyme crystals, liposomal encapsulation and permeation enhancers have resulted in limited performance. In addition, intestinal transmucosal delivery devices suffer from early release of drug into the lumen and deficiencies in the penetrating member function.
An additional complexity is finding the balance between the conflicting needs of the formulation. The formulation is required to protect the active agents from naturally present chemical and biologic barriers, while also promoting fast and efficient release when the delivery device is deployed at the intestine wall. More specifically, it is required to have a high degree of strength or durability to resist the conditions of the intestine lumen and preserve details of shape on micron-size needles for effective subsequent penetration of the intestine wall. On the other hand, it must also have the ability to release a drug prior to the disengagement from the intestine wall and preferably not too early, as this increases the risk of early drug release into the lumen and subsequent waste. In addition, the formulative conditions for the intestine lumen environment can negatively affect release in the interstitial space of the intestine tissue. In addition, many polymers used in the area of microneedles result in swelling which are not relevant for shape sensitive penetrating members. Thus, numerous challenging properties in design of these delivery devices exist. If these contradicting needs are overcome, this could open the option of delivering biologics via the intestine tissue.
Accordingly, although transmucosal drug delivery offers certain advantages over conventional oral delivery, it would be beneficial to promote innovations in formulation of intestine tissue penetrating members such that the strength and shape is maintained during exposure to the harsh conditions of the intestine environment without negatively affecting the timely release of the active agent in the intestine lumen wall and specifically to the interstitial space of the intestine wall.
Embodiments of the present disclosure include members, devices, systems, and methods for delivery of an active agent across or within an internally located soft tissue, for example an intestine wall. The invention further provides members, devices, systems, and methods for delivery of active agents across or within the intestine wall after exposure to the intestine environment wherein an active agent which chemically degrades, is poorly absorbed, and/or is not well tolerated in the lumen of the gastrointestinal tract. In various embodiments, the present invention provides biodegradable soft tissue or intestine tissue penetrating members specialized for exposure to the intestine lumen environment and subsequent delivery of an active agent across or within a soft tissue and especially the small intestine lumen wall. Thus, present invention can be effective in reducing undesired early release of an active agent into the intestine lumen (prior to penetration of the penetrating member across or within the lumen wall) and during exposure to the intestinal lumen environment (including the mucosal layer). This is especially important for active agents which may be sensitive to mechanical, biologic, or chemical degradation under typical intestine conditions. In various embodiments, the penetrating member is specifically designed and formulated such that it is resistant to degradation in the intestinal lumen environment and begins degradation and release active agent once safely positioned in the interstitial space, a specific layer of the intestinal soft tissue. This degradation and release of active agent also needs to occur in a relatively rapid manner to ensure delivery of active agent to the blood prior to disengagement of the penetrating member but without the associated risk of early release prior to deployment at the wall.
In one aspect, there is provided an oral device for delivery of an active agent across or within the small intestine lumen wall comprising:
wherein when the penetrating member is subject to simulating intestine conditions such as in vitro dissolution testing employing a USP II apparatus with dissolution medium at 37° C., 10-30 mM or preferably 30 mM buffer, pH 6.5 with fasted state simulating intestinal fluid (FaSSIF), the active agent is released from the penetrating member at a rate such that:
In general, the penetrating member continues to maintain strength, size in any dimension (e.g., length) and/or shape and/or prevent active agent release during the exposed period, i.e., while being exposed to the intestine lumen environment. Said another way, during an exposed period, the penetrating member resists chemical, biologic or mechanical degradation or diffusion, or the loss of structural integrity of the formulation as a whole.
Thus, in various embodiments of any of the aspects presented, the solid controlled-release penetrating member, when subject to in vitro dissolution testing using simulating intestine conditions for an exposed period of more than 1 minute, more than 3 minute, more than 5 minutes, more than 8 minutes, more than 10 minutes, more than 15 minutes, more than 20 minutes or between 1 and 30 minutes, between 1 and 20 minutes, between 1 and 10 minutes, 5 and 30 minutes, between 5 and 20 minutes, between 5 and 10 minutes, 10 and 30 minutes, between 10 and 20 minutes, 15 and 30 minutes, between 15 and 20 minutes, between 10 and 15 minutes, there is substantially no release of active agent or substantially no change in size of the penetration member.
In various embodiments of any of the aspects presented, the present disclosure provides solid controlled-release penetrating member (“penetrating member”) and systems thereof wherein the active pharmaceutical ingredient (“API”) or active agent release is controlled until exposure to the target layer in the tissue, the interstitial space or lamina propria layer, for example, in the small intestine lumen wall. In some embodiments, the active agent is released at a rate, preferably within 15 minutes to three hours from delivery and exposure to the intestinal lumen. Said another way, the solid controlled-release penetrating member is resistant to active agent release as measured for example using in vitro simulated or ex vivo simulated models for a protected period of time and provides a controlled or controlled release of an active agent during a controlled release period of time. The controlled or controlled release of an active agent is at a decreased rate compared to a standard immediate release profile of an oral formulation or transdermal immediate release formulation. The controlled release of an active agent is at an increased rate compared to a standard transdermal microneedle depot as measured in blood or an in vitro simulated or ex vivo simulated model.
In various embodiments of any of the aspects presented, the tissue solid controlled-release penetrating member, when subject to in vitro dissolution testing employing a USP II apparatus with dissolution medium at 37° C., 30 mM buffer, pH 6.5 to 7.5 with fasted state simulating intestinal fluid (FaSSIF) for 10 minutes, substantially no active agent is released.
In various embodiments of any of the aspects presented, the tissue solid controlled-release penetrating member or tip thereof, when subject to in vitro dissolution testing employing a USP II apparatus with dissolution medium at 37° C., 30 mM buffer, pH 6.5 to 7.5 with fasted state simulating intestinal fluid (FaSSIF) for 10 minutes, substantially no change in any one dimension or substantially no change in tip diameter or less than 20% or 10% or 5% or 3% or 1% change in size compared to the starting size of any dimension.
In various embodiments, the outer intestine release container can be an enteric coating or layer surrounding the drug delivery device (e.g., an enteric capsule) or alternatively an enteric coated soft gel cap. The term enteric is generally used to describe materials that are stable at relatively highly acidic pH conditions (e.g., pH of less than about 5.5) and susceptible to dissolution at relatively alkaline pH conditions (e.g., pH of between about 6 and about 9). In some embodiments, the wherein the intestine release container at least partially or fully contains an array of penetration members as well as the intestine wall deployment assembly.
In various embodiments of any of the aspects presented, the solid controlled-release penetrating member is an array or a plurality of penetrating member (e.g., microneedles). In some embodiments, the solid controlled-release penetrating member array has an active agent in an amount which makes up a portion of a therapeutically effective dose of at least one therapeutic agent or active agent. In some embodiments, the total amount of therapeutic agent within the array to produce a desired therapeutic effect is less than an amount to produce a corresponding effect if the agent was orally delivered in a capsule without the oral device. In some examples, the total active agent in the array of members is in an amount of more than 2 mg, more than 4 mg, more than 6 mg, more than 8 mg or in an amount of between 2-10 mg. In some embodiments, the active agent is in solid, semi-solid or liquid form within the solid penetrating member.
In various embodiments of any of the aspects presented, the tissue solid controlled-release penetrating member of any one of the aspects, comprises active agent loaded microparticles contained or shaped as a microneedle. In some embodiments, the penetrating member comprises a first molding material. In some embodiments, the penetrating member comprises a mixture of a) a polymer first molding material and b) a second molding material comprising rigid particles (e.g., microparticles) dispersed therein, wherein the first molding material is micro molded into the plurality of microneedles. In some embodiments, the penetrating member comprises an enteric coating or layer and a molding material comprising rigid particles dispersed therein, wherein the enteric coating is placed in the mold and a molding material with rigid particles are micro molded into the plurality of microneedles.
In some embodiments of any of the aspects presented, a solid controlled-release penetrating member is operatively connected to an intestine wall deployment assembly. The skilled artisan is referred, for example, to US Publication No. 2020/0276426 filed on Feb. 28, 2020 and U.S. Pat. No. 10,980,750, filed on Jun. 8, 2020, both of which are incorporated by reference herein in their entireties. In some examples, the penetrating members are bound to a rigid or pliable substrate. In some embodiments, multiple penetration members are each connected to a common pliable substrate at respective bases of the multiple penetration members. In other embodiments, the penetrating member is configured to be bound to a pliable substrate which is folded to be contained in a container and to be delivered from the container to penetrate and be advanced into the lumen wall by the application of force on the penetrating member or substrate thereof. In some examples, the total force applied to the penetration members or substrate is about 2 to 5 psi.
In some applications, the shape of the expandable member in its expanded form takes up a partial volume of the intestine at that location and applies a force on only part of the circumference of the inner wall of the intestine thereby serving as a temporary anchor that holds the drug delivery device in position for penetration of the penetrating members. The expandable member does not apply force to facing intestinal walls along axial extents thereof.
In various embodiments, the solid controlled-release penetrating member further comprises an outer coating of intestine environment protective component. In various embodiments, the intestine environment protective component surrounds or coats the controlled release coating. In various embodiments, the tip is at least partially coated, or the tip is formulated as a separate but adjacent and distal extension of the active agent formulation. In various embodiments, the solid controlled-release penetrating member comprises an intestine environment protective component and a tip coating. In some embodiments, the active agent is specifically released in the general area of the interstitial space of the intestine due to the choice of intestine environment protective component which may also target the pH specific to the interstitial space.
In various embodiments, the controlled release formulation includes an active agent and controlled release component. In some embodiments, the solid controlled-release penetrating member comprising the active agent is: i. a mixture of active agent and controlled release component; or ii. an immediate release active agent inner core and controlled release coating.
The control release coating may include pH sensitive (e.g., cationic acrylic/methacrylic copolymer or acrylic/methacrylic copolymer having a pH threshold at about 6.5) or sustained release polymers or excipients.
Sustained release polymers include for example lipophilic coatings. Lipophilic coatings may include an excipient selected from the list consisting of: polyglycolide (PGA), polylactide (PLA), poly-epsilon-caprolactone, poly dioxanone (a polyether-ester), poly lactide-co-glycolide, polyamide esters, polyalkalene esters, polyvinyl esters, polyvinyl alcohol, and polyanhydrides.
Typically, in various embodiments, coatings mentioned throughout, are located in a layer externally located relative to the active agent inner (e.g., inner core), and form the tip coating, controlled release coating or intestine environment protective component. Coatings may have a width of between 2 and 25 μm and preferably less than 10 μm. In addition, one may measure a combined thickness of multiple layers of coatings, for example, the outer control release coating and intestine environment protective component and the combined thickness may be less than 50 μm.
In some embodiments, the immediate release active agent inner core can be a hollow shell with dry active agent, or an active agent admixed with a biodegradable excipient or polymer. For example, immediate release active agent inner core may include any one or more biodegradable polymers having monomer units designed for drug delivery. Relevant examples of biodegradable polymers include but are not limited to: natural polymers; polyesters including poly(lactic acid) (“PLA”), poly(lactic-co-glycolic acid) (“PLGA”), poly(caprolactone) (“PCL”), poly(glycolic acid) (“PGA”); chitosan; poly(ortho esters) such as (POE I, POE II, POE III or POE IV); hyaluronic acid; poly(anhydrides); poly(amides); poly(ester amides); poly(phosphoesters); poly(alkyl cyanoacrylates) (“PACA”). Additional excipients for immediate release of an active agent are also possible and can include for example dextrin, polysaccharides, arginine, carboxymethylcellulose, water miscible polymers including polyethylene glycol (“PEG”), polyvinyl alcohol (“PVA”) or polyvinylpyrrolidone (“PVP”) (optionally in combination with polymers containing a cationic acrylic/methacrylic copolymers, said polymers being based on methacrylic acid esters and a small portion of trimethyl aminoethyl methacrylate chloridei [such as, Eudragit RS 100®] or based on meth acryl acid esters and a small portion of amino methacrylate copolymers [such as Eudragit E 100®]. Other options are also possible and can be chosen by those skilled in the art.
The active agent inner core can further comprise a stabilizer, buffer, polymer, antioxidant, diluent, lubricant, binder, or plasticizer and can be chosen by those skilled in the art. Surfactant can also be added and can be especially important to contribute to structural stability and reduce exposure of hydrophobic regions so as to decrease or limit interface-induced aggregation and protein-protein interaction and resulting mechanical stress. Examples include poloxamers, polysorbate 20 and especially polysorbate 80. Relevant ratios to active agent may depend on the active agent and can be calculated.
In some embodiments, the mixture comprises a controlled release component such as a non-disintegrating carrier matrix selected from the list consisting of acacia, sodium alginate, gelatin, carboxymethyl cellulose sodium, methylcellulose, ethylcellulose, cellulose acetate or polyacrylates (e.g., ammonio methacrylate copolymers i.e., Eudragit RS/RL), polyethylene glycol (PEG), polyvinyl polymers, methylcellulose (e.g., HPMC, HPC) and ethylcellulose.
In another embodiment, the mixture comprises a controlled release component selected from the list consisting of polyvinyl polymers, methylcellulose and ethylcellulose. The ethyl cellulose may be a low-viscosity ethyl cellulose. When a low-viscosity ethyl cellulose is used, the mixture further comprises a pore-forming agent selected from the group consisting of hydroxypropyl cellulose and hydroxypropyl methylcellulose. The matrix may additionally include further excipients such as binders, fillers, process enhancers such as lubricants and glidants. In some embodiments, the excipients do not include a disintegrant.
In some embodiments of any of the aspects presented, the one or more solid controlled-release penetrating member are at least partially covered with polymer and specifically a slow-release polymer which delays exposure of the penetrating member. Examples include a pH-dependent enteric coating having sensitivity at pH greater than 6.0, PLGA, PLGA/PEG, PLGA/PAA, an aqueous pore forming film (water soluble ethyl cellulose and water soluble hydroxypropyl cellulose), polymer or semi-permeable film (e.g., combination of PVP K30 and hydrophilic polyethylene glycol such as PEG 6000), silk fibroin, a lipophilic (PCL, PDO, HCO) or hydrophobic polymer. This coating may additionally include pore formers, plasticizers, and processing enhancing agents such as lubricants.
Suitable the pore formers are known in the art and include HPC, HPMC, polyethylene glycol, poloxamer, povidone or a saccharide. Preferably, it is HPC, HPMC, polyethylene glycol, or povidone. Suitable amounts of pore formers in the coating polymer to pore former of 5:1 to 2:1 or 5:1 to 1:1 and preferably ratios of 100:35 to 100:45.
In various embodiments, the solid controlled-release penetrating member includes an outer control release coating comprises any suitable control release coating forming polymers which enable diffusion-based controlled release known in the art for instance: polyacrylates such as ammonio methacrylate copolymers (Eudragit RS/RL), polyvinylacetate, hydroxypropyl methylcellulose (optionally with ethylcellulose), carboxymethylcellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone (optionally with carboxymethylcellulose), alginates (e.g., sodium alginate or alginate/chitosan), methylcellulose, lipophillic poly-ε-caprolactone and ethyl cellulose. In a preferred embodiment, the outer controlled release coating is ethylcellulose, cellulose acetate, or polyacrylates such as ammonio methacrylate copolymers (Eudragit® RS or RL), polyvinylacetate or combinations thereof. The coating further includes a plasticizer. The amount of plasticizer is typically between 8 and 35% or preferably 10 to 25% relative to the control release polymer.
In some embodiments, the control release coating comprises a low-viscosity ethyl cellulose, a pore-forming agent, and a plasticizer. The low-viscosity ethyl cellulose and a pore-forming agent may be present in a ratio of the pore-forming agent to low-viscosity ethyl cellulose of about 9:1 to about 1:1. The low-viscosity ethyl cellulose and a pore-forming agent may be present in a ratio of the pore-forming agent to low-viscosity ethyl cellulose of about was 9:1 to 5:5 or 7:4 to 4:5. Relevant ratios include but are not limited to 9:1, 8:2, 6:4, 5:5 and 4:5. In some cases, control release coating having a low-viscosity ethyl cellulose may further comprise a plasticizer such as triethyl citrate.
In some embodiments, the control release coating comprises a hydroxypropyl cellulose or hydroxypropyl methylcellulose having a viscosity of about 4 cP to about 14 cP.
In some embodiments, the solid controlled-release penetrating member has an outer control release coating which is a sustained release or cationic acrylic/methacrylic copolymer.
Thus, in some embodiments, the acrylic/methacrylic copolymer is cationic. In some embodiments, the acrylic/methacrylic copolymer is non-biodegradable. In some embodiments, the acrylic/methacrylic copolymer has a high or low permeability.
In some embodiments, the acrylic/methacrylic copolymer has high permeability. The (meth)acrylate copolymer may be composed of 50 to 70% by weight of methyl methacrylate, 20 to 40% by weight of ethyl acrylate and more than 7 up to 12% by weight of a salt of 2-trimethylammoniumethyl methacrylate, preferably 2-trimethylammoniumethyl methacrylate chloride (Eudragit® RL type). More specifically, a suitable copolymer comprises 65% by weight of methyl methacrylate, 30% by weight of ethyl acrylate and 10% by weight of 2-trimethylammoniumethyl methacrylate chloride. The glass transition temperature of said copolymer is about 70° C. Specific example include but are not limited to Eudragit RL 100®, Eudragit RL PO®, Eudragit RL 12.5° and Eudragit RL 30D®.
In some embodiments, the acrylic/methacrylic copolymer has low permeability. The (meth)acrylate copolymer may be composed of 50 to 70% by weight of methyl methacrylate, 20 to 40% by weight of ethyl acrylate and 7 to 2% by weight of a salt of 2-trimethylammoniumethyl methacrylate, preferably 2-trimethylammoniumethyl methacrylate chloride. The glass transition temperature of said copolymer is about 65° C. Specific examples include but are not limited to Eudragit® Type RS and specifically Eudragit RS 100®.
In some embodiments, the controlled release coating comprises an acrylic/methacrylic copolymer and further comprises a pore former. In some embodiments, the partial coating is a non-swelling polymer. In some embodiments, the partial coating has a thickness of between 2 and 50 μm. In some embodiments, the partial coating has a thickness of between 2 and 25 μm. In some embodiments, the partial coating has a thickness of less than 10 μm.
In some embodiments, the solid controlled-release penetrating member includes a multicompartment or double coating structure. The double coating structure may include a controlled release component as a first acrylic/methacrylic copolymer (for example a Eudragit RL 100®, Eudragit RL PO®, Eudragit RL 12.5®, Eudragit RL 30D®, Eudragit RS 100®) and an additional outer coating of intestine environment protective component is an enteric acrylic/methacrylic copolymer (for example, Eudragit S 100®, a combination of Eudragit S 100® and Eudragit L 100®, Eudragit S 12.5®).
In a particular embodiment of the invention, the inner active agent core can be layered with a coating such that the drug is released from the formulation specifically in the interstitial space of the intestine tissue. Thus, in some embodiments, the outer control release coating is a pH dependent film-forming polymer having a pH threshold at about pH 6.5 or above. These film-forming polymers are typically used in targeted delivery of an active agent to the colon where the pH is higher than the small intestine lumen however, in this case, it is used to provide a targeted release of the active agent to the interstitial space of the intestine tissue after penetration of the penetrating member.
In specific embodiments of the outer control release coating, the pH dependent film-forming polymer is an acrylate polymer. The acrylate polymer may be an anionic copolymer of (meth)acrylic acid and (meth)acrylic acid C1-4 alkyl ester. The acrylate polymer may be a copolymer of methacrylic acid and ethyl acrylate. The acrylate polymer may be an anionic co-polymer of methacrylic acid and methacrylic acid methyl ester. The acrylate polymer may have a ratio of methacrylic acid to methacrylic acid methyl ester is about 1:1 to 1:2. Preferably, the acrylate polymer may have a ratio of methacrylic acid to methacrylic acid methyl ester is about 1:2. The acrylate polymer may be an have pH threshold is of about 7 meaning that it is insoluble below pH 6.5 and, more preferably, is insoluble below pH 7. The acrylate polymer may be an anionic poly (methacrylic acid/methyl methacrylate) copolymer with an acid to ester ratio is of 1 to 2, and/or a molecular weight of approximately 135,000 and/or and a pH threshold is of about 7 such as Eudragit S100® or Eudragit S 12.5 or mixtures thereof. Other examples include other copolymers such as methyl methacrylate and methacrylic acid such as Eudragit® FS30D. The coating can also be a mixture and include an additional methacrylic acid and ethyl acrylate copolymer such as one which has a pH threshold of about 6.0 including for example a methacrylic acid and methyl methacrylate copolymers (1:1 ratio) such as Eudragit L-100® or Eudragit L12.5®.
Other pH dependent film-forming polymer having a pH threshold at about pH 6.5 or above may also be used. Examples include cellulose polymers or a polyvinyl-based polymers. For example, a cellulose polymer can be cellulose acetate phthalate (“CAP”), cellulose acetate trimellitate (“CAT”) or hydroxypropyl methylcellulose acetate succinate. Specifically, hydroxypropyl methylcellulose acetate succinate (“HPMC-AS”) such as type H which has a low succinoyl to acetyl group ratio or hydroxypropyl methylcellulose phthalate (HPMCP) such as HP-55 grade can also be used. Exemplary polyvinyl-based polymers may include polyvinyl acetate phthalate (“PVAP”). In addition, shellac (for example SSB® Aquagold).
In various embodiments of any of the aspects presented, the solid controlled-release penetrating member includes a tissue penetrating shape. In some embodiments, the shape is a tip having a sharp edge and shaped to promote penetration of soft tissue or more specifically, intestine tissue and resist degradation during exposure to an intestine lumen environment. In some embodiments, the shape includes a distal tip having mechanical strength to support penetration though the mucosal layers of the intestine and reach the interstitial space. In some embodiments, the mechanical strength of the tip remains substantially consistent during the intestinal lumen exposure period such that penetration though the mucosal layer of the intestine is smooth or efficient. Said another way, the tip resist degradation during exposure to an intestine lumen environment.
Thus, in various embodiments of any of the aspects presented, the tissue penetrating shape or distal tip of the solid controlled-release penetrating member is coated or covered on the outside with a protective layer or coating. Alternatively, the tip is formulated as a distinct section at the distal end of the penetrating member such that it is slow dissolving and distinct from the formulation having an active agent. In this case, the tip has a distinct formulation and is an adjacent and distal extension of the controlled release mixture or coated inner immediate release active agent. Thus, resistance to degradation or mechanical strength especially under conditions of the intestinal lumen, is preserved by the protective coating, covering, or the distinct distal end. Application of the at least partial coating or layer may be via spray coating, 3D printing, dipping, dropping, inkjet or immersion. The fabrication of the slow dissolving tip section may be by pouring the formulation into a mold, centrifuging, and allowing to set prior to adding an additional layer or coating with active pharmaceutical. Both the additional layer and the coating can provide additional strength required for supporting the piercing of soft tissue. Relevant materials for formulation include any pharmaceutically acceptable water insoluble, hydrophobic polymers, or non-degradable polymers including but not limited to an alginic acid and salts thereof, polyvinylpyrrolidone (e.g., Polyvidone® CL, Kollidon® CL, Polyplasdone® XL-10), poly (lactic-co-glycolic acid, thermoplastic polyester such as Polylactic acid, or polyvinyl acetate copolymer.
In various embodiments, the intestine environment protective component is associated with one or more tissue solid controlled-release penetrating member s whether formulated within the penetrating member or in at least a partial layer or coating surrounding the active agent. The intestine environment protective component may be configured to protect the penetrating member from degradation (e.g., from the environment of the gastrointestinal tract) until it is advanced into tissue.
In some embodiments, the intestine environment protective component can undergo time dependent degradation during an exposed period under the pH conditions of the intestine lumen. For example, the intestine environment protective component may be configured to protect the tissue solid controlled-release penetrating member and thereby substantially reduce or eliminate a risk of premature release of a drug where it is not readily absorbed; thus, such an intestine environment protective component of the penetrating member may help retain the treatment efficacy of the dose of drug provided in the drug delivery device.
The intestine environment protective component can form at least a partial outer coating on the controlled release coating. It may include a lipophilic coating including an excipient selected from the list consisting of: polyglycolide (PGA), polylactide (PLA), poly-epsilon-caprolactone, poly dioxanone (a polyether-ester), poly lactide-co-glycolide, polyamide esters, polyalkalene esters, polyvinyl esters, polyvinyl alcohol, and polyanhydrides) or a film-forming polymeric material having a pH threshold at about 6.5 or above. In specific embodiments, it may include PLGA or PLGA/PEG or PLGA/PAA, an aqueous pore forming film (water soluble ethyl cellulose and water soluble hydroxypropyl cellulose), a polymer or semi-permeable film (e.g., combination of PVP K30 and hydrophilic polyethylene glycol such as PEG 6000), or a silk fibroin or a lipophilic (PCL, PDO, HCO) or hydrophobic polymer. In some examples, the layer or coating is at least a partial coating provided by spray coating, dipping, dropping, inkjet, immersion. In some examples, the layer or coating is a film comprising HPMC (for example HPMC E15), plasticizer (such as propylene glycol) and a disintegrating agent.
In some embodiments of the invention, the intestine environment protective component is a pH dependent film-forming polymer having a pH threshold at about pH 6.5 or above or specifically having a threshold of about 7.0. These film-forming polymers are typically used in targeted delivery of an active agent to the colon where the pH is higher than the small intestine lumen however, in this case, it is used to protect from early release in the stomach and small intestine but provide an additional and novel effect of targeting release of the active agent to the interstitial space of the intestine tissue after penetration of the penetrating member.
In specific embodiments of the intestine environment protective component, the pH dependent film-forming polymer is an acrylate polymer. The acrylate polymer may be an anionic copolymer of (meth)acrylic acid and (meth)acrylic acid C1-4 alkyl ester. The acrylate polymer may be a copolymer of methacrylic acid and ethyl acrylate. The acrylate polymer may be an anionic co-polymer of methacrylic acid and methacrylic acid methyl ester. The acrylate polymer may have a ratio of methacrylic acid to methacrylic acid methyl ester is about 1:2. The acrylate polymer may be an anionic poly (methacrylic acid/methyl methacrylate) copolymer with an acid to ester ratio is of 1 to 2, and/or a molecular weight of approximately 135,000 and/or and a pH threshold is of about 7 such as Eudragit S100® or Eudragit S 12.5 or mixtures thereof. Other examples include other copolymers such as methyl methacrylate and methacrylic acid such as Eudragit® FS30D. The coating can also be a mixture and include an additional methacrylic acid and ethyl acrylate copolymer such as a methacrylic acid and methyl methacrylate copolymers (1:1 ratio) such as Eudragit® L-100®.
Other pH dependent film-forming polymer having a pH threshold at about pH 6.5 or above may also be used. Examples include cellulose polymers or a polyvinyl-based polymers. For example, a cellulose polymer can be cellulose acetate phthalate (“CAP”), cellulose acetate trimellitate (“CAT”) or hydroxypropyl methylcellulose acetate succinate. Specifically, hydroxypropyl methylcellulose acetate succinate (“HPMC-AS”) such as type H which has a low succinoyl to acetyl group ratio or hydroxypropyl methylcellulose phthalate (HPMCP) such as HP-55 grade can also be used. Exemplary polyvinyl-based polymers may include polyvinyl acetate phthalate (“PVAP”). In addition, shellac (for example SSB® Aquagold).
In some embodiments, the intestine environment protective component can undergo ion, time, or pH dependent degradation during a release period under the pH conditions of the intestine lumen.
In various embodiments, the present disclosure provides solid controlled-release penetrating member s specifically configured to meet the requirements of an intestine wall deployment assembly. An example of a device is referenced in U.S. Pat. No. 10,675,248, filed Aug. 14, 2018, and incorporated herein by reference.
In some embodiments, the intestine wall deployment assembly is configured to position the penetrating member adjacent to the intestinal lumen wall; and apply a force to said penetrating member so as to penetrate the wall. In some embodiments, the intestine wall deployment assembly is configured to deploy the penetrating member at the wall of the intestine lumen within 15 minutes of passing the pyloric valve or within 15 minutes of exposure to the small intestinal environment after at least partial release from an intestine release container, such as an enteric capsule. The oral device for delivery of active agent across or within a lumen of the small intestine is configured to subsequently apply a force to the penetrating members which are shaped to promote penetration and eventually penetrate the intestine tissue. In addition, the penetrating members of the present invention are specifically configured to meet the requirements of an oral device for delivery of active agent across or within a lumen of the small intestine which is maintained adjacent to the intestine lumen wall for more than 15 minutes or more than 30 minutes or about 15 minutes to 240 minutes or about 15 minutes to about 120 minutes.
In some embodiments, intestine wall deployment assembly is deployed adjacent to the intestinal lumen wall within 15 minutes of exposure to the small intestine environment. In some embodiments, the intestine wall deployment assembly is configured to be deployed in the lumen of the intestine within 15 minutes of exposure to the small intestinal environment and for about 240 minutes. In some embodiments, the intestine wall deployment assembly is configured to be deployed in the lumen of the intestine within 15 minutes of exposure to the small intestinal environment and for about 180 minutes. In some embodiments, the intestine wall deployment assembly is configured to be deployed in the lumen of the intestine within 15 minutes of exposure to the small intestinal environment and for about 120 minutes.
In various embodiments, preventing release of an active agent or maintenance of the size and/or shape of the solid controlled-release penetrating member is for an exposed period wherein less than 10% of the active agent is released after exposure to the intestinal environment and prior to penetration, for example within 15 minutes of release from the intestinal release container or exposure to the small intestine lumen environment. In some embodiments, more than 90% is released during the release period while the penetration member is positioned in the wall. A typical release period may be within 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 60minutes, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 120 minutes, 180 minutes, or 240 minutes of exposure to the intestinal environment.
In various embodiments of any of the aspects presented, exposure to the intestinal lumen environment is for an exposed period of time prior to provide for intestine luminal wall deployment of the one or more penetrating members. The exposed period of time to the intestinal lumen environment may be greater than 1 minute, greater than 5 minutes, greater than 10 minutes, greater than 15 minutes, greater than 20 minutes, greater than 25 minutes or greater than 30 minutes.
In other embodiments, the exposed period of time to the intestinal lumen environment is between 5 and 30 minutes, between 10 and 30 minutes, between 15 and 30 minutes or between 20 minutes and 30 minutes. In some embodiments, the exposed period of time is greater than 5 minutes or less than 15 minutes. Combinations of the above-referenced ranges are also possible (e.g., between 15 and 20 minutes). Other ranges are also possible.
In certain embodiments of any of the aspects or embodiments presented, the release period of time for the active agent is sufficient to ensure that most of the active agent is deposited within the intestinal wall such that active agent does not chemically degrade in the intestinal lumen environment. In some embodiments, the release period of time (i.e., the time for release of the active agent from the one or more penetration members) may be greater than 10 minutes, greater than 20 minutes, greater than 30 minutes, greater than 45 minutes, greater than 1 hour, greater than 2 hours or greater than 3 hours or greater than 4 hours. In some embodiments, the release period of time (e.g., during which there is release to the interstitial space) is between 10 minutes and 5 hours, 20 minutes and 5 hours, 30 minutes and 5 hours, 1 hour and 5 hours, 10 minutes and 4 hours, 20 minutes and 4 hours, 30 minutes and 4 hours, 1 hour and 4 hours, 10 minutes and 3 hours, 20 minutes and 3 hours, 30 minutes and 3 hours, 1 hour and 3 hours, 10 minutes and 2 hours, 20 minutes and 2 hours, 30 minutes and 2 hours or 60 minutes and 120 minutes, 10 minutes and 90 minutes, 20 minutes and 90 minutes, 30 minutes and 90 minutes or 60 minutes and 90 minutes or 10 minutes and 60 minutes, 20 minutes and 60 minutes, 30 minutes and 60 minutes. Combinations of the above-referenced ranges are also possible (e.g., greater than 15 to 30 minutes) Other ranges are also possible.
In certain embodiments of any of the aspects or embodiments presented, the release period of time for the active agent can be measured by a change in size such that there is less than 15% change or less than 10% or less than 8% or less than 5% or less than 3% or less than 2% change in size of the penetration member in any dimension during an exposed period. In certain embodiments of any of the aspects or embodiments presented, the release period of time for the active agent can be measured by a change in weight such that less than 15% change or less than 10% or less than 8% or less than 5% or less than 3% or less than 2% change in weight per penetrating member is measured.
In any of the embodiments described herein, the intestine wall deployment assembly may apply minimal or no force to facing intestinal walls when deployed in the lumen of the intestine and under conditions without intestinal peristalsis. Said another way, the force of opposing intestinal walls does not cause the penetration of the penetrating members. In some embodiments, the intestine wall deployment assembly is configured to be deployed in the lumen of the intestine and apply no force to facing intestinal walls.
In various embodiments of the present invention, the intestine wall deployment assembly comprises:
In another aspect of the present invention, there is provided a method of penetrating the mucosal tissue to deliver an active agent comprising: converting a pliable expandable member from an constrained configuration to an expanded configuration, said expandable member being operably connected to one or more solid controlled-release penetrating member in an intestinal protected from comprising a layer or film or pore forming polymer (e.g., a plurality of microneedles) which are exposed to the intestine environment for a period of time; enzymatic, chemical, or mechanical degradation of a layer or film or pore forming polymer to expose an exposed form of the one or more penetrating members; penetrating the mucosal barrier with one or more solid controlled-release penetrating member; and releasing active agent over a release period of time. In some embodiments, the exposed period of time is greater than 5 minutes or less than 15 minutes. In some embodiments, the release period of time is between 15 minutes and 2 hours.
In another aspect of the present invention, there is provided a method of delivering an active agent across or within the small intestine lumen wall, the method comprising the steps of: deploying a drug delivery device (e.g., patch) adjacent to a small intestine lumen wall said drug delivery device comprising one or more solid controlled-release penetrating member s (e.g., a plurality of microneedles), a pliable base and an expandable member; exposing the one or more penetrating members (e.g., a plurality of microneedles), pliable base and an expandable member to the intestinal fluid for a period of time and subsequently, penetrating the mucosal tissue with one or more solid controlled-release penetrating members (e.g., a plurality of microneedles) that extend from, or are extendable from, the expandable member at a selected time after the drug delivery device is deployed in the lumen; and releasing an active agent in a controlled manner over a period of between 15 minutes and 4 hours such that the active agent is delivered through the plurality of microneedles into the mucosal tissue.
In another aspect of the present invention, there is provided a method of delivering an active agent across or within the small intestine lumen wall, the method comprising the steps of:
In another aspect of the present invention, there is provided a method of delivering an active agent across or within the small intestine lumen wall, the method comprising the steps of:
In another aspect of the present invention, there is provided a method for delivering an active agent across or within the small intestine lumen wall, the method comprising the steps of:
In various embodiments of any of the aspects presented, the solid controlled-release penetrating member has a length suitable to reach the interstitial space in the intestine lumen wall.
In some embodiments, the solid controlled-release penetrating member is conical, cylindrical, tubular, pyramid-shaped, cube, pyramid or a hook-shaped. In some examples, the penetrating member is having a pyramid shape. In some embodiments, a penetrating member has a length less than about 1 mm. In some embodiments, the penetrating member has a length of about 20 to 900 μm, 200 to 1000 μm or 500 to 900 μm or 700 to 800 μm. In some embodiments, the greatest radius of the penetration member is or 100 and 400 μm. In some embodiments, a penetrating member has a maximum diameter or length at the base of the penetrating members between 100 to 1000, or 100 to 600 or 100 to 500 or 100 to 400 or 50 to 1000, or 50 to 600 or 50 to 500 or 50 to 400 μm or 150 to 300 μm.
In some embodiments, the one or more solid controlled-release penetrating members is arranged in an array as a plurality of members, e.g., as microneedles. In some embodiments, array includes about 100-150 penetrating members per cm2. In some embodiments, the array or plurality of penetrating members or microneedles are operatively connected to a pliable base. The pliable base may be folded or rolled to be contained in a container for oral delivery. In all embodiments, the pliable base protects the penetrating member from exposure to fluid and no additional layer or coating surrounds the penetrating member on the pliable base end. In some embodiments, the plurality of microneedles is an amount of about 1000 to 2000 or about 1300 to 1500. In some embodiments, the array includes a range of longitudinal sizes ranging between 200-1000 μm. In some embodiments, the penetrating members are spaced more than 0.2mm or more than 0.5 mm apart from one and other. In some embodiments, the penetrating members are spaced less than 4 mm or less than 3 mm or less than 2 or less than 1mm apart from one and other. In some embodiments, the penetrating members are spaced about 0.25 to 5 mm or 0.25 to 3 mm or 0.5 to 2 mm apart from one and other.
It should be noted that intestine environment protective component and the degradable component can be embodied by one component with altering characteristics dependent on the environmental conditions. In this case, one component may be triggered to release active agent when certain conditions are met such as pH, viscosity, ion strength, polarity, diffusion, erosion, pressure-based fluid convection or lipophilic conditions, each being specific to the intestine wall tissue. In this case, the distinguishing propertied of the interstitial space compared to the intestinal lumen environment can be used to select a relevant polymer to control the release in the desired target location.
In some embodiments of any of the aspects presented, the array of microneedles is covered as a whole by the intestine environment protective component or controlled release coating.
In some embodiments of any of the aspects presented, the intestine environment protective component is configured to gradually expose the array of penetration members via biologic, mechanical or chemical degradation (, e.g., via dissolving or disintegrating or chemical degradation of excipients). In some embodiment, the intestine environment protective component does not impede exposure of a compartment in a device but rather makes up part of the penetration member.
The present disclosure provides formulations for one or more penetration members operably coupled to an intestine wall deployment assembly and uses thereof. In one aspect, the present disclosure provides an oral device for delivery of active agent across or within a lumen of the small intestine of an active agent across or within the small intestine lumen wall in a subject comprising:
In some embodiments, the intestine wall deployment assembly is configured to position the solid controlled-release penetrating member adjacent to an intestinal lumen wall and cause the penetration member to pierce the lumen wall. In one example, an intestine wall deployment assembly is operably coupled to a patch or array of penetrating members and wherein the patch is a gas driven expandable member for patch deployment which is activated by the intestinal liquids to produce CO2 gas.
In another aspect, an orally administered drug delivery device is provided that includes a intestine release container and an intestine wall deployment assembly configured for intestine wall deployment and further comprising one or more penetrating members configured for: (i) preventing active agent release and/or maintaining shape and/or strength in the intestine lumen environment for an exposed period of time; and (ii) subsequent release across or within the small intestine lumen wall over a release period of time of the drug during transmucosal penetration of the penetration member.
In yet another aspect of the present invention, there is provided an oral device for delivery of active agent across or within a lumen of the small intestine of an active agent across or within the small intestine lumen wall, the formulation comprising:
In some embodiments, an intestine wall deployment assembly includes: i. an expandable member that is associated with one or more solid controlled-release penetrating member s, said expandable member having proximal and distal surfaces that face in generally opposite directions and configurable in a compacted configuration, an unconstrained configuration, and an expanded configuration; and ii. a gas generating compartment in fluid communication with the expandable member.
In some embodiments, the solid controlled-release penetrating member are elongated and sized and configured to penetrate a mucosal barrier of the intestinal wall to release an active agent and comprising: an active agent, an intestine environment protective component for maintaining strength and/or shape and/or resisting active agent release during exposure to the intestinal lumen environment for a period of time and an active agent release component for subsequent release of the active agent across of within the small intestine lumen wall for a period of time to release the active agent.
In some embodiments, the expanded shape system is sized and shaped to maintain contact with the intestinal wall (e.g., of the upper small intestine including the duodenum or jejunum) by applying an outwardly directed pressure to the intestinal wall to allow for one or more penetration members to transport at least a portion of the therapeutic agent across the mucosa of the intestine or specifically upper small intestine including the jejunum or duodenum.
In yet another aspect, a method is provided for penetrating the mucosal tissue to deliver an active agent comprising:
In another aspect, presented is a method of delivering an active agent across or within the small intestine lumen wall, the method comprising the steps of:
In another aspect, a method is provided for delivering an active agent across or within the small intestine lumen wall, the method comprising the steps of:
In some embodiments, the choice of excipients involved in degrading or dissolving the container, exposing of the members as well as releasing of the active agent into the tissue of the small intestine are dependent on specific environmental conditions in the lumen, mucosal layers and/or interstitial space. Environmental conditions include but are not limited to pH, ion strength, buffer capacity, or enzymes in the at that point of time.
In some embodiments, strength is measured by applying a constant or limited range of penetration force over area on a defined surface without affecting the shape in any dimension and maintaining strength is less than 5% change in strength at the two timepoints.
In another aspect, there is provided a method for delivering an active agent across or within the small intestine lumen wall, the method comprising the steps of:
In yet another aspect of the present invention, there is provided a method for delivering an active agent across or within the small intestine lumen wall, the method comprising the steps of:
In some embodiments, the active agent release component can include microsphere, one or multiple layers, active agent disposed in a polymer matrix.
There are a number of methods for providing a sustained release film which are then used to coat the solid controlled-release penetrating member. For example, a coating may be prepared by applying and then drying a formulation such as one of the following:
For the present disclosure to be more readily understood, certain terms are defined below. Additional definitions for the following terms and other terms are set forth throughout the specification.
As used herein, “drug”, “active agent”, “therapeutic” or “medicine” may be used interchangeably and includes small molecules, biologics, diagnostics, or active pharmaceutical ingredients used to treat or diagnose a patient. They can refer to any agent that, when administered, has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect. Generally, an active agent may refer to more than one active agent. Examples of active agents that may be suitable for use include but are not limited to chemotherapeutic agent, interferon, an antibody, an antibiotic, growth hormone, parathyroid hormone, a glucose regulating agent, an insulin compound, an incretin hormone, a GLP-1 compound or exenatide, antiviral, protease inhibitor or an anti-seizure compound or other active agents which would otherwise chemically degrade or have limited permeability if released within the intestine lumen of the gastrointestinal tract. In various embodiments of any of the aspects presented, the active agent is a peptide sequence, protein, an enzyme, a polysaccharide, or a polynucleotide, amino acids, nucleotides, carbohydrates, sugars, lipids, nucleoproteins, glycoproteins, lipoproteins, steroids, etc. whether naturally occurring or artificially created (e.g., by synthetic or recombinant methods) that are commonly found in cells and tissues. Specific classes of biologics include, but are not limited to, enzymes, receptors, neurotransmitters, hormones, cytokines, cell response modifiers such as growth factors and chemotactic factors, antibodies, vaccines, haptens, toxins, interferons, ribozymes, anti-sense agents, plasmids, DNA, and RNA. In some embodiments of any of the aspects presented, the active agent is in an amount of the active agent to produce a desired therapeutic effect is less than an amount to produce a corresponding effect if the agent was orally delivered without enclosure in the ingestible formulation. In some embodiments of any of the aspects presented, the active agent is a combination of active agents. In some embodiments of any of the aspects presented, the active agent would chemically degrade, have limited permeability, or impose a deleterious effect on the subject if released within the lumen of the gastrointestinal tract. In some embodiments of any of the aspects presented, the active agent comprises a polypeptide that is chemically degraded or have limited permeability in the GI tract and the agent is delivered into the wall of the small intestine with minimal or no loss in binding affinity or specificity to a target binding site.
As used herein degrading includes but is not limited to biodegradation, dissolving or disintegration due to exposure to biological fluid.
As used herein, the intestinal wall for deployment of the device is typically the upper small intestine including but not limited to the duodenum or jejunum.
As used herein, “coating” may refer to complete or partial covering. The coat may be continuous, discontinuous, flat, or textured. They may be smooth or follow contours of pores that may be present on the surface which they are covering.
As used herein, pore-forming polymers are biocompatible and readily water-soluble such as hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol (PEG), polylactic (also termed polylactide), polyglycolic acid (also termed polyglycolide), a polylactic-polyglycolic acid copolymer, and polyvinyl alcohol.
As used herein, “microneedle” refers to a type of penetrating member which is typically a protrusion from the surface of a rigid or flexible base. Microneedles generally are shape objects and in theory can be of any shape or design as long as the microneedles are shaped to penetrate or pierce tissue and, in this case, intestinal tissue. A microneedle may be conical, cylindrical, tubular, pyramid-shaped, cube, pyramid or a hook-shaped. A microneedle may be straight, curved, or semi hook shaped. Without being bound to any particular theory, a curved microneedle can facilitate retention of a device disclosed herein at a target site. A microneedle may protrude at angle from a device surface, the microneedle having a base integrally connected to the surface, a tip distal to the base, and a body therebetween. A microneedle or a portion of a microneedle can be porous or non-porous. A microneedle or a portion of a microneedle is biodegradable in the intestinal tissue over a period of time. A plurality of microneedles used in accordance with the present disclosure may include a mixture of different microneedles. For instance, microneedles of the plurality may include microneedles having various lengths, base portion materials, body portion diameters (i.e., gauge), tip portion shapes, spacing between microneedles, coatings, etc.
Note that Eudragit® copolymers are commercialized by Evonik and their composition is known to the skilled artisan
Although intestinal wall is used throughout, there are some cases where the invention may equally apply to similar soft tissue.
The drawings are for illustration purposes only and should not introduce limitation.
The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawings.
Various embodiments of the invention can be used to deliver active agents or active pharmaceutical ingredients (“API”) that were previously only delivered by parenteral administration. In various embodiments, such therapeutic agents may include biotherapeutic agents (also described as biologics) or peptides.
An intestinal transmucosal drug delivery device is provided for deployment or placement at the intestinal lumen wall after oral administration or due to surgical placement and generally maintained for the duration of delivery of an active agent within or to the lumen wall so long as anchorage in the wall is maintained. Key to successful delivery of an active agent without early release into the GI tract where it made degrade is the penetrating member. This one component is required to encompass many conflicting goals including: maintenance of shape and structure without early release of active agent during exposure to intestinal lumen conditions (which include both the fluid in the lumen and mucosal tissue) such that penetration is effective during a deployment at the lumen wall; subsequent release of active agent once positioned in the intestine lumen wall while maintaining anchorage in tissue; subsequent biodegradation.
A transmucosal drug delivery device is provided for deployment in the lumen of the intestine, preferably at the upper small intestine (including but not limited to the duodenum or jejunum). The deployment, or placement, of the device as well as the mechanism by which to initiate penetration of the penetration member can be by any method known in the art including that disclosed in WO2020035857.
A number of embodiments of penetration members suitable for use in accordance with the present invention are illustrated in
In one embodiment, a number of solid controlled-release penetrating members 2 is arranged on a pliable member to form an array 1 of penetrating members 2. The longitudinal sectional view of penetrating members 21-29 and 122, 127 and 129 according to the present invention are presented in
In various embodiments, the solid controlled-release penetrating member includes an active agent-controlled release formulation located in the center and/or protected by outer layers or coatings. In the various embodiments described in the following figures, the active agent an active agent which chemically degrades, is poorly absorbed, and/or is not well tolerated in the GI tract. In one embodiment, such as solid controlled-release penetrating member 21, the active agent formulation 30 is a mixture or matrix with an excipient such as a polymer. In various other embodiments such as the solid controlled-release penetrating member 22, the active agent formulation 31 is an active agent inner core and the controlled release component is present as at least a partial controlled release coating 50 on the active agent inner core to form a controlled release coating. In various other embodiments, the solid controlled-release penetrating member 23 includes a molding material 32A comprising active agent loaded rigid particles 32B such as microparticles dispersed within the molding material, wherein the molding material is shaped or molded (e.g., micromolded) into a penetrating member. The choice of molding material and or excipient or polymer are chosen such that the active agent activity is preserved during the manufacturing process, during shelf life of the product to preserve stability and for optimized environment created during release.
In various embodiments, the solid controlled-release penetrating member shown in 24, 25 and 26 includes a tip shaped to promote penetration and such that it has intestine environment resistance to degradation such that during exposure to the intestinal lumen environment, the penetrating member undergoes less than 10% change in size of penetration member in any dimension at 10 minutes during an intestine lumen exposed period or less than 10% release of active agent at 10 minutes. Note that when the penetrating member is a microneedle, the tip may be especially prone to breakage. Thus, in some embodiments, the tip is enforced as exemplified the additional tip coating 40 located on the distal end of penetrating member 24 and as a partial external coating on the distal end of active formulation 33. In another example, penetrating member 25 includes an active agent formulation 34 (in this case active agent loaded microparticles contained or shaped as a penetrating member), having an adjacent and distal extension of the controlled release formulation to form an intestine resistant tip 41, for example as can be prepare by adding a tip formulation to a mold, centrifuging the formulating in mold and drying to form a tip layer or coating, and subsequently, adding a second formulation containing the active agent to fill the remaining volume of the mold. In this case, the tip is formulated as a distinct layer or coating which is slow dissolving at the tip 41 or 42 and prepared as part of a bilayer penetrating member. In this case, during exposure to the intestinal lumen, there is less than 10% change in size of penetration member in any dimension at 10 minutes during an intestine lumen exposed period or less than 10% release of active agent in 10 minutes. This approach may also include alternative shapes of molds including penetrating member 26, having tip 42 and active agent formulation 35. Thus, there are two methods, a tip coating approach which surrounds at least of portion of the tip of the active agent formulation to form a penetrating member or an adjacent formulation which forms the tip itself and resides adjacent to the active agent formulation. Both may be effective in achieving the structural integrity of the tip required for subsequent penetrating in the soft tissue of the intestine after exposure to the intestine lumen environment for an exposure period. Note that a coating or adjacent tip may be used on any active agent formulation—whether the active agent formulation is exemplified by any of 21, 22 or 23.
In additional embodiments such as penetrating member 29, an intestine environment protective component or controlled release coating 52 may surround the previous layers including the active agent formulation 38 and the tip 45 (which may be formulated as a coating as described in 40 or adjacent layer as described for tip 41), such that the intestine environment protective component or controlled release coating 52 ensures that degradation resulting from exposure to the intestinal lumen environment, does not affect the ability of the tip to subsequently penetrate the intestinal tissue and reach the target layer, the interstitial space where drug can be released and reach the blood or lymphatic system.
In alternative embodiments, such as penetrating member 27 and 28, an additional coating or layer of controlled release coating or intestine environment protective component 51 or 52, may be present under or adjacent to a tip formulation. Coating 51 and 52 may be a sustained release polymer or pH sensitive or cationic acrylic/methacrylic copolymer. For example, a film-forming polymeric material such an enteric acrylic/methacrylic copolymer which has a pH threshold of above 6.5 or about 7.0 or above may be used. In some embodiments, the tip formulation 43, 44 and 45 may be formulated as slow dissolving at the tip and prepared as part of a bilayer penetrating member or alternatively as a tip coating and may be a coating at least partially surrounding the intestine environment protective component which at least partially surrounds the active agent formulation 36. Alternatively, the active agent formulation 37 may have an intestine environment protective component 52 at least partially surrounding the active agent formulation and further including an adjacent formulation which forms tip 44, at the distal end of penetrating member 28. In these embodiments, the active agent formulation 36, 37 and 38 may be a mixture or matrix with an excipient such as a polymer as exemplified in 21, an active agent formulation having an active agent inner core and the controlled release component is present as at least a partial coating on the active agent inner core to form a controlled release coating, as exemplified in 22 or alternatively, as active agent loaded rigid particles such as microparticles dispersed within the molding material as exemplified in 23.
In some embodiments displayed in
In some embodiments displayed in
Any of the above described embodiments, ensures that there is substantially no degradation nor change in shape or size of the penetrating member resulting from exposure to the intestinal lumen environment such that there is little to no effect on the ability of the tip to subsequently penetrate the intestinal tissue and reach the target layer, the interstitial space, where the active agent can be released from the penetrating member and reach the blood within less than the desired time and especially before release of the intestine wall deployment assembly disengages from the wall.
In some embodiments of any of the aspects presented, the one or more penetration members comprise an active agent and an enteric polymer having a threshold or sensitivity to degradation at a pH greater than 6.5 or about 7.0. In some embodiments, the enteric polymer forms at least a partial layer around a formulated active agent. In one example, a methyl acrylate methacrylic acid copolymer such as Eudragit® enteric polymer or more specifically a methyl acrylate-methyl methacrylate-methacrylic acid copolymer such as Eudragit® S or Eudragit® L30D55 can be used. It should be recognized to those in the art that during the coating process and curing temperature, the stability of the active agent should be preserved. It should be recognized to those in the art that these copolymers can be used alone or with a plasticizer. Such layers are normally applied using a liquid medium, and the nature of the plasticizer depends upon whether the medium is aqueous or non-aqueous. Plasticizers for use with aqueous medium include propylene glycol, triethyl citrate, acetyl triethyl citrate or Citroflex® or Citroflex® A2. Non-aqueous plasticizers include these, and diethyl and dibutyl phthalate and dibutyl sebacate. A preferred plasticizer is Triethyl citrate.
In some embodiments, two or more layers are provided. In one example, the one or more penetration members comprise:
In another embodiment, two or more layers are provided such that the penetration members comprise:
In another embodiment, three layers or coatings are provided such that the penetration members comprise:
A description is now provided for the fabrication process used to make various embodiments of the solid controlled-release penetrating member of the present invention. Methods for fabricating the solid controlled-release penetrating member including methods for fabricating a plurality of penetrating members and especially an array of penetrating members operably coupled to a pliable base are provided. The process and formulation were designed to meet challenges presented by the sensitivity to degradation of the preferred active agents, peptides, and proteins. In addition, the process and formulation support the operable connection of the penetrating members to a pliable base.
For preparing an array of penetrating members operably connected to a pliable base, a 3M mold can be used to produce a PDMS mold. Optionally, if a tip layer or coating is desired, a formulation for the tip can be poured prior to the active agent and centrifuged for 30 min for concentration in the tip. The active agent is then prepared with relevant excipients which are relevant to preserve activity and placed or poured into the mold. The mold is centrifuged to remove excess and then a pliable base formulation such as PVP solution can be applied on the mold and centrifuged and dried under room temperature conditions.
Once the array of penetrating members or microneedles are prepared, layers or coatings may be applied onto the core by any suitable means known to a person skilled in the art. For example, it can be applied using classical coating or dipping techniques to add a tip coating, control release coating or intestine environment protective component. Some selection in methods is necessary in order that the pliable base is not affected in terms of function.
In the masked dip coating or protective masking, for example, an array of penetrating members is dipping into the coating liquid and plate masking is used to avoid coating the pliable base.
Alternatively, a thin film dip coating method can be used where a thin coating liquid film is applied by rolling using a doctor blade C-ii, once again with control of the height of the coating and preventing the coating of the pliable base be keeping the height lower than the height of the penetrating member. As a result, when the microneedles are dipped into the thin liquid film, the coating liquid is unable to rise significantly and thus is unable to touch the base.
An additional option may be using spray coating or frozen spray coating. The solvent-based solution of coating is applied and when the target weight gain is reached, the formulation can be dried, and a further coating can be applied. Multiple coatings can thus be applied. Note that the speed of the member exiting the solution, coating solution viscosity, drying time and presence of surfactant between dips contribute to uniform coating.
An additional method may include powder layering where a dry formulation or polymer using rotor dry layering is applied and a subsequent liquid aqueous binder is applied.
In all stages of the process, drying temperatures remain under 40 degrees Celsius, optionally under vacuum conditions. Exact ratios of excipients may be varied as well as coating % and in vitro release measured for further optimization.
An exemplary intestine wall deployment assembly suitable for use in accordance with the present disclosure is illustrated in
The intestine release container 201, is configured to dissolve in the small intestine environment 202 contained within the small intestine walls 203 (e.g., a duodenum, jejunum, and/or ileum walls) and resist degradation in the gastric environment and until arriving in the lumen of the small intestine 210 of the subject. Typically, intestine release container 201 is pH-sensitive and may be configured to dissolve within 15 minutes (e.g., within 10 or 5 minutes). Typically, the intestine release container 201 has a length of at least 5 mm, no more than 30 mm, and/or between 5- and 30-mm dissolving. Typically, the intestine release container 201 has a diameter of between 3 and 6 mm or between 4 and 5 mm.
The oral drug delivery device 200 in
For some applications, drug delivery device 200 is biodegradable along the gastrointestinal tract. For some applications, an expandable member 208 comprises an elastomer, such as polyethylene or silicone which does not biodegrade but rather passes safely through the gastrointestinal tract without sharp or rigid elements. For some applications, there are no sharp or rigid parts of the drug delivery device except for biodegradable penetration members (microneedles).
Typically, an expandable member 208 is configured such that expanded shape in
The expanded expandable member 208 has proximal surface 204 of an expandable member which eventually contacts the intestinal wall 203 in expanded form, thereby bringing one or more penetrating members 206 into contact with intestinal wall 203. Typically, one or more penetrating members 206 penetrate intestinal wall 203, to release the active agent without inducing release in the lumen. In addition, one or more expandable members 208 may serve as a temporary anchor that holds the drug delivery device in place during active agent delivery. Once expanded, proximal surface 204 of an expandable member 208 establishes good (complete or nearly complete) contact with intestinal wall 203, as shown in
Generally, the outer intestine release container may be sized and shaped to be swallowed and pass into the gastrointestinal tract with release in the small intestine specifically. Enteric formulations for capsules for example are known in the art. The capsule container is necessarily configured to resist degradation in the stomach and degrade in whole or in part during passage in the small intestine. In some variations, the material of the capsule container may be configured to degrade in an intestinal environment (e.g., in the small intestine) in which the pH is at least about 5.5. For example, the capsule container may be formed from a material and/or include a coating that is configured to degrade in an environment having a pH of at least 5.5, at least 6.0, at least 6.5, at least 7.0, at least 7.1.
The capsule container may be configured to dissolve in its entirety, and/or the capsule container may break apart into smaller pieces (e.g., due to dissolvable joints or seams) to facilitate release of the delivery device into the small intestine for deployment.
In general, devices described herein can comprise an expanding member coupled to the penetrating members for advancing the penetrating member into the wall of the small intestine. In some embodiments, the expandable member has proximal and distal surfaces that face in generally opposite directions. In some embodiments, the one or more penetrating members (e.g., microneedle array) extend from the proximal surface thereof.
The expanding and pliable member can be configurable in a compacted configuration, an unconstrained configuration, and an expanded configuration. In some embodiments, the expanding and pliable member is configured to be initiated by exposure to the intestinal lumen environment. In some embodiments of the present invention, the expanding and pliable member can be configurable in a compacted configuration where it is retained within the capsule in a folded state.
For examples, the expanding and pliable member can be folded to define one or more creases, which define respective inner and outer crease sides, wherein at least one of the tissues penetrating members is coupled to the patch along the inner crease sides.
In some embodiments, the pliable member can inscribe a circle having a diameter of between 2 and 10 cm when the patch is unconstrained. In some embodiments, the pliable member can inscribe a circle having a diameter of less than 8 cm, less than 6 cm, less than 5 cm minutes or about 4 cm. Combinations of the above-referenced ranges are also possible (e.g., between 2 and 5 cm).
In some embodiments, the expanded pliable member, when deployed in the lumen of the intestine without intestinal peristalsis, applies no force to facing intestinal walls along axial extents thereof. Unlike a balloon based expanded member which expands such that there is contact with most of the surfaces of the intestine wall, the expanded pliable member in this case is in surface contact in only one area of the circumference of the intestine lumen.
In some embodiments, the upper surface of the expandable member contacts an intestinal wall, thereby bringing the penetration members into contact with the intestinal wall. In some embodiments at least 50% or at least 75% or at least 80% or at least 90% of the penetration members are coupled to the proximal surface of the patch. In another embodiment, at least 50% or at least 75% or at least 80% or at least 90% of the area of the upper surface of the expandable member is in direct contact with the intestine tissue.
In some embodiments, the expandable member gradually moves from an unconstrained configuration to an expanded configuration due to gas pressure. The gas pressure resulting from the gas generating reaction is sufficient to advance the penetrating member into the wall of the small intestine.
Gas motor can be coupled to the release element and can be configured to be initiated by release of the release element which subsequently causes expansion of the expanding member for advancing the penetrating member into the wall of the small intestine. The gas generating compartment or compartments can be defined by i. a substantially water-permeable and substantially gas-impermeable, polymer layer shaped to define at least one window therethrough, and a liquid and humidity permeable and substantially gas-impermeable wetting layer, which entirely covers the at least one window and is sealed to the polymer layer around the at least one window; and ii. a gas-generating formulation that produces gas upon contact with liquid or humidity, the gas-generating formulation disposed within one or more compartments. The gas generating formulation can include sodium bicarbonate and is typically disposed in a vicinity of the at least one window which permeable to humidity or water.
In an embodiment, techniques and apparatus described in one or more of the following applications are combined with techniques and apparatus described herein:
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and sub-combinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
| Number | Date | Country | |
|---|---|---|---|
| 63240378 | Sep 2021 | US |
